

# OncomineWorld 2022

## A virtual NGS education meeting

**ThermoFisher**  
SCIENTIFIC



### April 7, 2022: Event program

To accommodate our global audience, live presentations will be held over a 24-hour period in three live sessions. Please consult this program for talks in your time zone.

In addition to the listed live presentations, enjoy access to dozens of on-demand presentations from past OncomineWorld events, visit virtual laboratories to learn about the many applications of genomic profiling in precision oncology research, and explore interactive and educational virtual features.

### Asia Pacific Live Session 1: 12:00–14:40 p.m. SGT

#### Welcome:

Luca Quagliata, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: 12:00–12:05 p.m. SGT

#### Part 1: General education

**Lung pathology in the era of targeted therapies in patients with advanced NSCLC:** Dr. Trishe Leong, Medical Director of Pathology and Director of Anatomical Pathology, St. Vincent's Hospital Melbourne, 12:05–12:25 p.m. SGT

#### Part 2: Companion diagnostic testing

**Exploratory factors relevant to success of the Ion Torrent™ Oncomine™ Dx Target Test:** Dr. Rie Sakakibara, Assistant Professor, Department of Respiratory Medicine, Tokyo Medical and Dental University, 12:25–12:45 p.m. SGT

**Experience of *ROS1* CDx platforms in the central laboratory of South Korea:** Dr. Tae-Jung Kim, Director of Pathology, Yeouido St. Mary's Hospital, 12:45–13:05 p.m. SGT

Q&A: 13:05–13:20 p.m. SGT

Break: 13:20–13:30 p.m. SGT

#### Part 3: Clinical oncology research

**Peter MacCallum Cancer Centre validation of the Oncomine™ Precision Assay and experience with the Ion Torrent™ Genexus™ System:** Dr. Chelsee Hewitt, Peter MacCallum Cancer Centre, 13:30–14:00 p.m. SGT

Q&A: 14:00–14:10 p.m. SGT

Genexus System virtual demo with live Q&A:  
14:10–14:40 p.m. SGT



## Europe and the Americas Live Session 2: 15:00–17:30 p.m. CET

### Welcome:

Luca Quagliata, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: **15:00–15:05 p.m. CET**

### Part 1: General education

**RET aberrations and *EGFR* exon 20 insertions testing in the complex NSCLC biomarker landscape:** Dr. Fernando López-Ríos, MD, PhD, Department of Pathology, Doce de Octubre University Hospital Madrid, **15:05–15:25 p.m. CET**

### Part 2: IVDR update

**An update on IVDR implementation plans and the Thermo Fisher Scientific NGS IVDR product pipeline:** Dr. Jon Sherlock, Director of Product Management, Oncology; and Anna Sadio, Regulatory Manager, Thermo Fisher Scientific, **15:25–15:45 p.m. CET**

**Q&A: 15:45–16:00 p.m. CET**

**Break: 16:00–16:10 p.m. CET**

### Part 3: Clinical oncology research

**Implementation of next-generation sequencing in solid tumor testing using the Genexus platform:** Dr. Marco Volante, Professor of Pathology, Department of Oncology, University of Turin; Director Pathology Unit, San Luigi Hospital, Orbassano, Turin, **16:10–16:30 p.m. CET**

**Implementing the Ion Torrent™ OncoPrint™ Leader-J assay for testing IGHV somatic hypermutation status in CLL samples:** Dr. Robyn Marshall, Oncolab Diagnostics, Pretoria, **16:30–16:50 p.m. CET**

**Q&A: 16:50–17:00 p.m. CET**

**Genexus System virtual demo with live Q&A: 17:00–17:30 p.m. CET**

## Americas Live Session 3: 12:00–14:30 p.m. PT

### Welcome:

Luca Quagliata, PhD, BCMAS, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific: **12:00–12:05 p.m. PT**

### Part 1: General education

***HER2* mutation—an emerging biomarker in NSCLC:** Matthew Beer, Medical Affairs Director, Thermo Fisher Scientific, **12:05–12:25 p.m. PT**

**Q&A: 12:25–12:35 p.m. PT**

### Part 2: Clinical oncology research

**Analytical validation of a next-generation sequencing laboratory-developed test:** John Williamson, Sr. Technical Project Manager; and Rafael D. Ramirez, Global Business Development Manager, Thermo Fisher Scientific, **12:35–12:55 p.m. PT**


**Break: 12:55–13:05 p.m. PT**

**Rapid next-generation sequencing for the study of acute myeloid leukemia:** Dr. Diana Morlote, Assistant Professor, Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham, **13:05–13:25 p.m. PT**

**Ion Torrent™ OncoPrint™ Precision Test on the Genexus System—first experience:** Dr. Daria Grafodatskaya, Assistant Professor Pathology and Molecular Medicine, McMaster University Hamilton, **13:25–13:45 p.m. PT**

**Q&A: 13:45–14:00 p.m. PT**

**Genexus System virtual demo with live Q&A: 14:00–14:30 p.m. PT**

 Learn more and register at **[labroots.com/ms/virtual-event/oncomineworld-2022](https://labroots.com/ms/virtual-event/oncomineworld-2022)**